BERA
종목 검색

ModernaMRNA

$223.4-3.4%11월 13일 종가 기준
시가총액 $90.4B

3달 전보다 +202.7%

세로선 = 임상·딜 이벤트 · 차트 위에서 스크롤하면 확대·축소, 확대 중엔 가로로 넘겨볼 수 있어요

지켜보기 의견AI 점수 68 / 100

mRNA 플랫폼 기술을 바탕으로 감염병 예방 백신과 다양한 치료제를 개발해요.

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, the company is reimagining how medicines are made to transform how diseases are treated and prevented. Its mRNA platform enables the development of vaccine and therapeutic candidates across multiple therapeutic areas.

진행 중인 임상과 AI 예측
  • Phase ?스파이크백스 코로나19 백신 시판 후 안전성 조사진행 중Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE
    80%
  • Phase ?모더나 코로나19 백신 접종 후 심근염 장기 경과 연구진행 중A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
    59%
  • Phase ?mRNA-1283 중장년층 코로나19 백신 비교 임상모집 중A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
    59%
  • Phase ?mRNA-1283 코로나19 변이 바이러스 백신 면역성 평가모집 중A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
    94%
  • Phase 3mRNA-1345 고위험군 RSV 백신 임상진행 중A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
    18%
  • Phase 3mRNA-1345 고령자 호흡기세포융합바이러스 백신 임상진행 중A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
    18%
  • Phase 2임산부 및 영아 대상 모더나 RSV 백신 mRNA-1345 임상진행 중A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
    11%
  • Phase 1mRNA-1345/1365 영유아 백신 안전성 임상진행 중A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
    64%
  • Phase 1mRNA-4157 고형암 단독 및 병용 암백신 임상진행 중Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
    48%
  • Phase 2고위험 흑색종 대상 맞춤형 암백신 mRNA-4157 병용 임상진행 중An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
    78%
  • Phase 1mRNA-4359 단독 및 면역관문억제제 병용 고형암 임상모집 중Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
    48%
  • Phase 3mRNA-1403 급성 위장염 예방 백신 성인 임상진행 중A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
    59%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.

홈으로 돌아가기